You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePosaconazole
Accession NumberDB01263
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionPosaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • Sch 56592
  • SCH-56592
  • SCH56592
  • Schering 56592
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NoxafilGastro-resistant tablet100 mgOral useMerck Sharp & Dohme Ltd2005-10-25Not applicableEu
Noxafilsuspension40 mg/mLoralMerck Sharp & Dohme Corp.2006-09-15Not applicableUs
NoxafilGastro-resistant tablet100 mgOral useMerck Sharp & Dohme Ltd2005-10-25Not applicableEu
Noxafiltablet, coated100 mg/1oralMerck Sharp & Dohme Corp.2013-11-25Not applicableUs
NoxafilConcentrate for solution for infusion300 mgIntravenous useMerck Sharp & Dohme Ltd2005-10-25Not applicableEu
Noxafilsolution18 mg/mLintravenousMerck Sharp & Dohme Corp.2014-03-13Not applicableUs
NoxafilOral suspension40 mg/mlOral useMerck Sharp & Dohme Ltd2005-10-25Not applicableEu
Posanoltablet (delayed-release)100 mgoralMerck Canada Inc2014-05-21Not applicableCanada
Posanolsolution18 mgintravenousMerck Canada Inc2014-11-24Not applicableCanada
Posanolsuspension40 mgoralMerck Canada Inc2007-06-06Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Posaconazole SpOral suspension40 mg/mlOral useSchering Plough Europe2005-10-25Not applicableEu
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII6TK1G07BHZ
CAS number171228-49-2
WeightAverage: 700.7774
Monoisotopic: 700.329708282
Chemical FormulaC37H42F2N8O4
InChI KeyRAGOYPUPXAKGKH-XAKZXMRKSA-N
InChI
InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1
IUPAC Name
4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-1-[(2S,3S)-2-hydroxypentan-3-yl]-4,5-dihydro-1H-1,2,4-triazol-5-one
SMILES
[H][C@@](C)(O)[C@]([H])(CC)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@]2([H])CO[C@](CN3C=NC=N3)(C2)C2=C(F)C=C(F)C=C2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Phenyl-1,3,4-triazole
  • Phenyl-1,2,4-triazole
  • Phenyltriazole
  • Substituted aniline
  • Dialkylarylamine
  • Phenol ether
  • Halobenzene
  • Fluorobenzene
  • Aniline
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Triazole
  • Oxolane
  • Azole
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with prolonged neutropenia from chemotherapy. Also for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole. Posaconazole is used as an alternative treatment for invasive aspergillosis, Fusarium infections, and zygomycosis in patients who are intolerant of, or whose disease is refractory to, other antifungals.
PharmacodynamicsPosaconazole is an antifungal agent structurally related to itraconazole. It is a drug derived from itraconzaole through the replacement of the chlorine substituents with flourine in the phenyl ring, as well as hydroxylation of the triazolone side chain. These modifications enhance the potency and spectrum of activity of the drug. Posaconazole can be either fungicial or fungistatic in action.
Mechanism of actionAs a triazole antifungal agent, posaconazole exerts its antifungal activity through blockage of the cytochrome P-450 dependent enzyme, sterol 14α-demethylase, in fungi by binding to the heme cofactor located on the enzyme. This leads to the inhibition of the synthesis of ergosterol, a key component of the fungal cell membrane, and accumulation of methylated sterol precursors. This results in inhibition of fungal cell growth and ultimately, cell death.
Related Articles
AbsorptionPosaconazole is absorbed with a median Tmax of approximately 3 to 5 hours.
Volume of distribution
  • 1774 L
Protein bindingPosaconazole is highly protein bound (>98%), predominantly to albumin.
Metabolism

Posaconazole primarily circulates as the parent compound in plasma. Of the circulating metabolites, the majority are glucuronide conjugates formed via UDP glucuronidation (phase 2 enzymes). Posaconazole does not have any major circulating oxidative (CYP450 mediated) metabolites. The excreted metabolites in urine and feces account for ~17% of the administered radiolabeled dose.

Route of eliminationThe excreted metabolites in urine and feces account for ~17% of the administered radiolabeled dose.
Half lifePosaconazole is eliminated with a mean half-life (t½) of 35 hours (range 20 to 66 hours).
Clearance
  • 32 L/hr
  • 51 L/hr [Single-Dose Suspension Administration of 200 mg, fasted]
  • 21 L/hr [Single-Dose Suspension Administration of 200 mg, nonfat meal]
  • 14 L/hr [Single-Dose Suspension Administration of 200 mg, high fat meal]
  • 91 L/hr [Single-Dose Suspension Administration of 400 mg, fasted]
  • 43 L/hr [Single-Dose Suspension Administration of 400 mg with liquid nutritional supplement (14 g fat)]
ToxicityDuring the clinical trials, some patients received posaconazole up to 1600 mg/day with no adverse events noted that were different from the lower doses. In addition, accidental overdose was noted in one patient who took 1200 mg BID for 3 days. No related adverse events were noted by the investigator.
Affected organisms
  • Aspergillis, Candida and other fungi
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.5499
Caco-2 permeable+0.5332
P-glycoprotein substrateSubstrate0.7822
P-glycoprotein inhibitor IInhibitor0.7338
P-glycoprotein inhibitor IINon-inhibitor0.8895
Renal organic cation transporterNon-inhibitor0.7323
CYP450 2C9 substrateNon-substrate0.8131
CYP450 2D6 substrateNon-substrate0.8354
CYP450 3A4 substrateSubstrate0.6683
CYP450 1A2 substrateNon-inhibitor0.8484
CYP450 2C9 inhibitorInhibitor0.5281
CYP450 2D6 inhibitorNon-inhibitor0.8667
CYP450 2C19 inhibitorNon-inhibitor0.6409
CYP450 3A4 inhibitorNon-inhibitor0.5532
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5074
Ames testAMES toxic0.5235
CarcinogenicityNon-carcinogens0.7341
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8919 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5306
hERG inhibition (predictor II)Inhibitor0.6661
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Concentrate for solution for infusionIntravenous use300 mg
Gastro-resistant tabletOral use100 mg
Oral suspensionOral use40 mg/ml
Solutionintravenous18 mg/mL
Suspensionoral40 mg/mL
Tablet, coatedoral100 mg/1
Solutionintravenous18 mg
Suspensionoral40 mg
Tablet (delayed-release)oral100 mg
Prices
Unit descriptionCostUnit
Noxafil 40 mg/ml suspension7.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2179396 No2001-04-172014-12-20Canada
CA2305803 No2009-12-222018-10-05Canada
US5661151 No1999-07-192019-07-19Us
US5703079 No1994-08-262014-08-26Us
US6958337 No1998-10-052018-10-05Us
US8263600 No2002-04-012022-04-01Us
US8410077 No2009-03-132029-03-13Us
US9023790 No2011-07-042031-07-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
logP5.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP4.71ALOGPS
logP5.41ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)14.83ChemAxon
pKa (Strongest Basic)3.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area111.79 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity200.71 m3·mol-1ChemAxon
Polarizability73.83 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Dominic De Souza, “PREPARATION OF POSACONAZOLE INTERMEDIATES.” U.S. Patent US20130203994, issued August 08, 2013.

US20130203994
General References
  1. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007 Jan 25;356(4):348-59. [PubMed:17251531 ]
  2. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 Jan 25;356(4):335-47. [PubMed:17251530 ]
  3. Bhattacharya M, Rajeshwari K, Dhingra B: Posaconazole. J Postgrad Med. 2010 Apr-Jun;56(2):163-7. doi: 10.4103/0022-3859.65281. [PubMed:20622401 ]
  4. Frampton JE, Scott LJ: Posaconazole : a review of its use in the prophylaxis of invasive fungal infections. Drugs. 2008;68(7):993-1016. [PubMed:18457464 ]
  5. Schiller DS, Fung HB: Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther. 2007 Sep;29(9):1862-86. [PubMed:18035188 ]
  6. Kwon DS, Mylonakis E: Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007 Jun;8(8):1167-78. [PubMed:17516880 ]
  7. Groll AH, Walsh TJ: Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther. 2005 Aug;3(4):467-87. [PubMed:16107193 ]
  8. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH: Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother. 2008 Oct;42(10):1429-38. doi: 10.1345/aph.1L005. Epub 2008 Aug 19. [PubMed:18713852 ]
  9. Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H: Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010 Jun;49(6):379-96. doi: 10.2165/11319340-000000000-00000. [PubMed:20481649 ]
External Links
ATC CodesJ02AC04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (183 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Posaconazole.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Posaconazole.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Posaconazole.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Posaconazole.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Posaconazole.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Posaconazole.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Posaconazole.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Posaconazole.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Posaconazole.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Posaconazole.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Posaconazole.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Posaconazole.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Posaconazole.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Posaconazole.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Posaconazole.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Posaconazole.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Posaconazole.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Posaconazole.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Posaconazole.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Posaconazole.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Posaconazole.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Posaconazole.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Posaconazole.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Posaconazole.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Posaconazole.
AmiodaroneThe metabolism of Posaconazole can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Posaconazole.
AmlodipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Amlodipine.
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Posaconazole.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Posaconazole.
AmrinoneThe risk or severity of adverse effects can be increased when Posaconazole is combined with Amrinone.
AnagrelidePosaconazole may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Posaconazole.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Posaconazole.
ApremilastThe metabolism of Apremilast can be decreased when combined with Posaconazole.
AprepitantThe serum concentration of Posaconazole can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Posaconazole.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Posaconazole.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Posaconazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Posaconazole.
ArtemetherThe metabolism of Artemether can be decreased when combined with Posaconazole.
AsenapineThe serum concentration of Posaconazole can be decreased when it is combined with Asenapine.
AsenapineThe metabolism of Asenapine can be decreased when combined with Posaconazole.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Posaconazole.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Posaconazole.
AtazanavirThe metabolism of Posaconazole can be decreased when combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Posaconazole.
AtomoxetineThe metabolism of Posaconazole can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Posaconazole.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Posaconazole.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Posaconazole.
AzelastineThe metabolism of Azelastine can be decreased when combined with Posaconazole.
AzelnidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Azelnidipine.
AzimilideThe risk or severity of adverse effects can be increased when Posaconazole is combined with Azimilide.
AzithromycinPosaconazole may increase the QTc-prolonging activities of Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Posaconazole.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Posaconazole.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Posaconazole.
BedaquilinePosaconazole may increase the QTc-prolonging activities of Bedaquiline.
BenidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Benidipine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Posaconazole.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Posaconazole.
BepridilThe risk or severity of adverse effects can be increased when Posaconazole is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Posaconazole.
BexaroteneThe serum concentration of Posaconazole can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Posaconazole.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Posaconazole.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Posaconazole.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Posaconazole.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Posaconazole.
BoceprevirThe metabolism of Posaconazole can be decreased when combined with Boceprevir.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Posaconazole.
BortezomibThe metabolism of Posaconazole can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Posaconazole can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Posaconazole.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Posaconazole.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Posaconazole.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Posaconazole.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Posaconazole.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Posaconazole.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Posaconazole.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Posaconazole.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Posaconazole.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Posaconazole.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Posaconazole.
BupropionThe metabolism of Bupropion can be decreased when combined with Posaconazole.
BuspironeThe metabolism of Buspirone can be decreased when combined with Posaconazole.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Posaconazole.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Posaconazole.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Posaconazole.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Posaconazole.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Posaconazole.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Posaconazole.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Posaconazole.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Posaconazole.
CarbamazepineThe metabolism of Posaconazole can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Posaconazole.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Posaconazole.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Posaconazole.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Posaconazole.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Posaconazole.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Posaconazole.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Posaconazole.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Posaconazole.
CeritinibThe serum concentration of Posaconazole can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Posaconazole.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Posaconazole.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Posaconazole.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Posaconazole.
ChloroquinePosaconazole may increase the QTc-prolonging activities of Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Posaconazole.
ChlorpromazinePosaconazole may increase the QTc-prolonging activities of Chlorpromazine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Posaconazole.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Posaconazole.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Posaconazole.
CilnidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Cilnidipine.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Posaconazole.
CimetidineThe serum concentration of Posaconazole can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Posaconazole.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Posaconazole.
CinnarizineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Cinnarizine.
CiprofloxacinPosaconazole may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Posaconazole.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Posaconazole.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Posaconazole.
ClarithromycinPosaconazole may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Posaconazole can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Posaconazole can be decreased when combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Posaconazole.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Posaconazole.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Posaconazole.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Posaconazole.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Posaconazole.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Posaconazole.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Posaconazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Posaconazole.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Posaconazole.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Posaconazole.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Posaconazole.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Posaconazole.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Posaconazole.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Posaconazole.
ClotrimazoleThe metabolism of Posaconazole can be decreased when combined with Clotrimazole.
ClozapinePosaconazole may increase the QTc-prolonging activities of Clozapine.
CobicistatThe metabolism of Posaconazole can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Posaconazole.
CocaineThe metabolism of Cocaine can be decreased when combined with Posaconazole.
CodeineThe metabolism of Codeine can be decreased when combined with Posaconazole.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Posaconazole.
ConivaptanThe serum concentration of Posaconazole can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Posaconazole.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Posaconazole.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Posaconazole.
CrizotinibThe metabolism of Posaconazole can be decreased when combined with Crizotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Posaconazole.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Posaconazole.
CyclosporineThe metabolism of Posaconazole can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Posaconazole.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Posaconazole.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Posaconazole.
DabrafenibThe serum concentration of Posaconazole can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Posaconazole.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Posaconazole.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Posaconazole.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Posaconazole.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Posaconazole.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Posaconazole.
DapsoneThe metabolism of Dapsone can be decreased when combined with Posaconazole.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Posaconazole.
DarodipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Darodipine.
DarunavirThe metabolism of Darunavir can be decreased when combined with Posaconazole.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Posaconazole.
DasatinibThe serum concentration of Posaconazole can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Posaconazole.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Posaconazole.
DeferasiroxThe serum concentration of Posaconazole can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Posaconazole.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Posaconazole.
DelavirdineThe metabolism of Posaconazole can be decreased when combined with Delavirdine.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Posaconazole.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Posaconazole.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Posaconazole.
DexamethasoneThe serum concentration of Posaconazole can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Posaconazole.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Posaconazole.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Posaconazole.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Posaconazole.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Posaconazole.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Posaconazole.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Posaconazole.
DidanosineDidanosine can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Posaconazole.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Posaconazole.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Posaconazole.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Posaconazole.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Posaconazole.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Posaconazole.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Posaconazole.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Posaconazole.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Posaconazole.
DihydroergotamineThe metabolism of Posaconazole can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Posaconazole.
DiltiazemThe metabolism of Posaconazole can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Posaconazole.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Posaconazole.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Posaconazole.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Posaconazole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Posaconazole.
DofetilideThe metabolism of Dofetilide can be decreased when combined with Posaconazole.
DolasetronPosaconazole may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Posaconazole.
DonepezilThe metabolism of Donepezil can be decreased when combined with Posaconazole.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Posaconazole.
DotarizineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Dotarizine.
DoxepinThe serum concentration of Posaconazole can be decreased when it is combined with Doxepin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Posaconazole.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Posaconazole.
DoxycyclineThe metabolism of Posaconazole can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Posaconazole.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Posaconazole.
DronedaroneThe metabolism of Posaconazole can be decreased when combined with Dronedarone.
DroperidolPosaconazole may increase the QTc-prolonging activities of Droperidol.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Posaconazole.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Posaconazole.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Posaconazole.
EfavirenzThe serum concentration of Posaconazole can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Posaconazole.
EfonidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Posaconazole.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Posaconazole.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Posaconazole.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Posaconazole.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Posaconazole.
EnzalutamideThe serum concentration of Posaconazole can be decreased when it is combined with Enzalutamide.
EperisoneThe risk or severity of adverse effects can be increased when Posaconazole is combined with Eperisone.
EpinastineThe serum concentration of Posaconazole can be decreased when it is combined with Epinastine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Posaconazole.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Posaconazole.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Posaconazole.
EquilinThe serum concentration of Equilin can be increased when it is combined with Posaconazole.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Posaconazole.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Posaconazole.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Posaconazole.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Posaconazole.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Posaconazole.
ErythromycinPosaconazole may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Posaconazole can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Posaconazole.
Eslicarbazepine acetateThe serum concentration of Posaconazole can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Posaconazole can be decreased when it is combined with Esomeprazole.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Posaconazole.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Posaconazole.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Posaconazole.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Posaconazole.
EstramustineThe metabolism of Estramustine can be decreased when combined with Posaconazole.
EstriolThe serum concentration of Estriol can be increased when it is combined with Posaconazole.
EstroneThe serum concentration of Estrone can be increased when it is combined with Posaconazole.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Posaconazole.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Posaconazole.
EthanolThe metabolism of Ethanol can be decreased when combined with Posaconazole.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Posaconazole.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Posaconazole.
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Posaconazole.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Posaconazole.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Posaconazole.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Posaconazole.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Posaconazole.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Posaconazole.
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Posaconazole.
EtravirineThe serum concentration of Posaconazole can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Posaconazole.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Posaconazole.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Posaconazole.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Posaconazole.
FamotidineThe serum concentration of Posaconazole can be decreased when it is combined with Famotidine.
FelbamateThe metabolism of Felbamate can be decreased when combined with Posaconazole.
FelodipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Felodipine.
FendilineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Fendiline.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Posaconazole.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Posaconazole.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Posaconazole.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Posaconazole.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Posaconazole.
FinasterideThe metabolism of Finasteride can be decreased when combined with Posaconazole.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Posaconazole.
FlecainidePosaconazole may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Posaconazole.
FluconazoleThe metabolism of Posaconazole can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Posaconazole.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Posaconazole.
FlunarizineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Flunarizine.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Posaconazole.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Posaconazole.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Posaconazole.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Posaconazole.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Posaconazole.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Posaconazole.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Posaconazole.
FlupentixolPosaconazole may increase the QTc-prolonging activities of Flupentixol.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Posaconazole.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Posaconazole.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Posaconazole.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Posaconazole.
FlutamideThe metabolism of Flutamide can be decreased when combined with Posaconazole.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Posaconazole.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Posaconazole.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Posaconazole.
FluvoxamineThe metabolism of Posaconazole can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be increased when Fosamprenavir is used in combination with Posaconazole.
FosamprenavirThe metabolism of Posaconazole can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Posaconazole can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Posaconazole can be decreased when it is combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Posaconazole.
Fusidic AcidThe serum concentration of Posaconazole can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Posaconazole is combined with Gabapentin.
Gadobenic acidPosaconazole may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Posaconazole.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Posaconazole.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Posaconazole.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Posaconazole.
GemifloxacinPosaconazole may increase the QTc-prolonging activities of Gemifloxacin.
GlipizidePosaconazole may increase the hypoglycemic activities of Glipizide.
GlyburideThe metabolism of Glyburide can be decreased when combined with Posaconazole.
GoserelinPosaconazole may increase the QTc-prolonging activities of Goserelin.
GranisetronPosaconazole may increase the QTc-prolonging activities of Granisetron.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Posaconazole.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Posaconazole.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Posaconazole.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Posaconazole.
HaloperidolPosaconazole may increase the QTc-prolonging activities of Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Posaconazole.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Posaconazole.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Posaconazole.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Posaconazole.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Posaconazole.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Posaconazole.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Posaconazole.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Posaconazole.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Posaconazole.
IbutilidePosaconazole may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Posaconazole can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Posaconazole resulting in a loss in efficacy.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Posaconazole.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Posaconazole.
ImatinibThe metabolism of Posaconazole can be decreased when combined with Imatinib.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Posaconazole.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Posaconazole.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Posaconazole.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Posaconazole.
IndapamideThe metabolism of Indapamide can be decreased when combined with Posaconazole.
IndinavirThe metabolism of Posaconazole can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Posaconazole.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Posaconazole.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Posaconazole.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Posaconazole.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Posaconazole.
IsavuconazoniumThe metabolism of Posaconazole can be decreased when combined with Isavuconazonium.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Posaconazole.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Posaconazole.
IsradipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Isradipine.
IsradipineThe metabolism of Posaconazole can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Posaconazole can be decreased when combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Posaconazole.
IvacaftorThe serum concentration of Posaconazole can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Posaconazole.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Posaconazole.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Posaconazole.
KetamineThe metabolism of Ketamine can be decreased when combined with Posaconazole.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Posaconazole.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Posaconazole.
KetoconazoleThe metabolism of Posaconazole can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Posaconazole.
LacidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Lacidipine.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Posaconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Posaconazole.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Posaconazole.
LansoprazoleThe serum concentration of Posaconazole can be decreased when it is combined with Lansoprazole.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Posaconazole.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Posaconazole.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Posaconazole.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Posaconazole.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Posaconazole.
LenvatinibPosaconazole may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Posaconazole.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Posaconazole.
LeuprolidePosaconazole may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Posaconazole.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Posaconazole.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Posaconazole.
LevofloxacinPosaconazole may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Posaconazole.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Posaconazole.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Posaconazole.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Posaconazole.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Posaconazole.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Posaconazole.
LisurideThe metabolism of Lisuride can be decreased when combined with Posaconazole.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Posaconazole.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Posaconazole.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Posaconazole.
LoratadineThe metabolism of Loratadine can be decreased when combined with Posaconazole.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Posaconazole.
LosartanThe metabolism of Losartan can be decreased when combined with Posaconazole.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Posaconazole.
LovastatinThe metabolism of Posaconazole can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Posaconazole can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Posaconazole can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Posaconazole.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Posaconazole.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Posaconazole.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Posaconazole is combined with Magnesium Sulfate.
ManidipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Manidipine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Posaconazole.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Posaconazole.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Posaconazole.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Posaconazole.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Posaconazole.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Posaconazole.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Posaconazole.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Posaconazole.
MethadonePosaconazole may increase the QTc-prolonging activities of Methadone.
MethanthelineThe serum concentration of Posaconazole can be decreased when it is combined with Methantheline.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Posaconazole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Posaconazole.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Posaconazole.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Posaconazole.
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Posaconazole.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Posaconazole.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Posaconazole.
MetiamideThe serum concentration of Posaconazole can be decreased when it is combined with Metiamide.
MetoclopramideThe serum concentration of Posaconazole can be decreased when it is combined with Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Posaconazole.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Posaconazole.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Posaconazole.
MianserinThe metabolism of Mianserin can be decreased when combined with Posaconazole.
MibefradilThe risk or severity of adverse effects can be increased when Posaconazole is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Posaconazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Posaconazole.
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Posaconazole.
MifepristoneThe metabolism of Posaconazole can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Posaconazole.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Posaconazole.
MitotaneThe serum concentration of Posaconazole can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Posaconazole.
ModafinilThe serum concentration of Posaconazole can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Posaconazole.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Posaconazole.
MontelukastThe metabolism of Montelukast can be decreased when combined with Posaconazole.
MorphineThe serum concentration of Morphine can be increased when it is combined with Posaconazole.
MoxifloxacinPosaconazole may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Posaconazole.
NadololThe serum concentration of Nadolol can be increased when it is combined with Posaconazole.
NafcillinThe serum concentration of Posaconazole can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Posaconazole.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Posaconazole.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Posaconazole.
NefazodoneThe metabolism of Posaconazole can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Posaconazole can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Posaconazole.
NetupitantThe serum concentration of Posaconazole can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Posaconazole can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Posaconazole.
NicotineThe metabolism of Nicotine can be decreased when combined with Posaconazole.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Posaconazole.
NiguldipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Posaconazole.
NilotinibThe metabolism of Posaconazole can be decreased when combined with Nilotinib.
NiludipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Niludipine.
NilvadipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Posaconazole is combined with Nimesulide.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Posaconazole.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Posaconazole.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Posaconazole.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Posaconazole.
NitrendipineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Nitrendipine.
NizatidineThe serum concentration of Posaconazole can be decreased when it is combined with Nizatidine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Posaconazole.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Posaconazole.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Posaconazole.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Posaconazole.
OfloxacinPosaconazole may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe serum concentration of Posaconazole can be decreased when it is combined with Olanzapine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Posaconazole.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Posaconazole.
OlaparibThe metabolism of Posaconazole can be decreased when combined with Olaparib.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Posaconazole.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Posaconazole.
OmeprazoleThe serum concentration of Posaconazole can be decreased when it is combined with Omeprazole.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Posaconazole.
OndansetronPosaconazole may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Posaconazole.
OsimertinibThe serum concentration of Posaconazole can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Posaconazole.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Posaconazole.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Posaconazole.
OxycodoneThe risk or severity of adverse effects can be increased when Posaconazole is combined with Oxycodone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Posaconazole.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Posaconazole.
PalbociclibThe serum concentration of Posaconazole can be increased when it is combined with Palbociclib.
PaliperidonePosaconazole may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Posaconazole.
PanobinostatPosaconazole may increase the QTc-prolonging activities of Panobinostat.
PantoprazoleThe serum concentration of Posaconazole can be decreased when it is combined with Pantoprazole.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Posaconazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Posaconazole.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Posaconazole.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Posaconazole.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Posaconazole.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Posaconazole.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Posaconazole.
PentamidinePosaconazole may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe metabolism of Posaconazole can be increased when combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Posaconazole.
PerflutrenPosaconazole may increase the QTc-prolonging activities of Perflutren.
PergolideThe metabolism of Pergolide can be decreased when combined with Posaconazole.
PerhexilineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Perhexiline.
PermethrinThe metabolism of Permethrin can be decreased when combined with Posaconazole.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Posaconazole.
PethidineThe metabolism of Pethidine can be decreased when combined with Posaconazole.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Posaconazole.
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Posaconazole.
PhenobarbitalThe metabolism of Posaconazole can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Posaconazole.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Posaconazole.
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Posaconazole.
PhenytoinThe metabolism of Posaconazole can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Posaconazole.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Posaconazole.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Posaconazole.
PimozidePosaconazole may increase the arrhythmogenic activities of Pimozide.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Posaconazole.
PinaveriumThe risk or severity of adverse effects can be increased when Posaconazole is combined with Pinaverium.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Posaconazole.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Posaconazole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Posaconazole.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Posaconazole.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Posaconazole.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Posaconazole.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Posaconazole.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Posaconazole resulting in a loss in efficacy.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Posaconazole.
PrazepamThe metabolism of Prazepam can be decreased when combined with Posaconazole.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Posaconazole.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Posaconazole.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Posaconazole.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Posaconazole.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Posaconazole.
PregabalinThe risk or severity of adverse effects can be increased when Posaconazole is combined with Pregabalin.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Posaconazole.
PrenylamineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Prenylamine.
PrimaquinePosaconazole may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Posaconazole can be increased when combined with Primidone.
ProcainamidePosaconazole may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Posaconazole.
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Posaconazole.
ProguanilThe metabolism of Proguanil can be decreased when combined with Posaconazole.
PromazinePosaconazole may increase the QTc-prolonging activities of Promazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Posaconazole.
PropofolThe metabolism of Propofol can be decreased when combined with Posaconazole.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Posaconazole.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Posaconazole.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Posaconazole.
QuazepamThe metabolism of Quazepam can be decreased when combined with Posaconazole.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Posaconazole.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Posaconazole.
QuinidineThe metabolism of Quinidine can be decreased when combined with Posaconazole.
QuinineThe serum concentration of Quinine can be increased when it is combined with Posaconazole.
RabeprazoleThe serum concentration of Posaconazole can be decreased when it is combined with Rabeprazole.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Posaconazole.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Posaconazole.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Posaconazole.
RanitidineThe serum concentration of Posaconazole can be decreased when it is combined with Ranitidine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Posaconazole.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Posaconazole.
RanolazineThe metabolism of Posaconazole can be decreased when combined with Ranolazine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Posaconazole.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Posaconazole.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Posaconazole.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Posaconazole.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Posaconazole.
RifabutinThe metabolism of Posaconazole can be increased when combined with Rifabutin.
RifampicinThe metabolism of Posaconazole can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Posaconazole.
RifapentineThe metabolism of Posaconazole can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Posaconazole.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Posaconazole.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Posaconazole.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Posaconazole.
RiociguatThe metabolism of Riociguat can be decreased when combined with Posaconazole.
RisedronateThe risk or severity of adverse effects can be increased when Posaconazole is combined with Risedronate.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Posaconazole.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Posaconazole.
RitonavirThe metabolism of Posaconazole can be decreased when combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Posaconazole.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Posaconazole.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Posaconazole.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Posaconazole.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Posaconazole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Posaconazole.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Posaconazole.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Posaconazole.
Roxatidine acetateThe serum concentration of Posaconazole can be decreased when it is combined with Roxatidine acetate.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Posaconazole.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Posaconazole.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Posaconazole.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Posaconazole.
SaquinavirPosaconazole may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Posaconazole can be decreased when combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Posaconazole.
SelegilineThe metabolism of Selegiline can be decreased when combined with Posaconazole.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Posaconazole.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Posaconazole.
SertindoleThe metabolism of Sertindole can be decreased when combined with Posaconazole.
SertralineThe metabolism of Sertraline can be decreased when combined with Posaconazole.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Posaconazole.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Posaconazole.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Posaconazole.
SildenafilThe metabolism of Posaconazole can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Posaconazole.
SiltuximabThe serum concentration of Posaconazole can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Posaconazole can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Posaconazole.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Posaconazole.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Posaconazole.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Posaconazole.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Posaconazole.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Posaconazole.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Posaconazole.
SotalolPosaconazole may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Posaconazole.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Posaconazole.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Posaconazole.
St. John's WortThe serum concentration of Posaconazole can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Posaconazole can be increased when it is combined with Stiripentol.
SucralfateSucralfate can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Posaconazole.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Posaconazole.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Posaconazole.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Posaconazole.
SulfisoxazolePosaconazole may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Posaconazole can be decreased when combined with Sulfisoxazole.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Posaconazole.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Posaconazole.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Posaconazole.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Posaconazole.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Posaconazole.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Posaconazole.
TAK-390MRThe serum concentration of Posaconazole can be decreased when it is combined with TAK-390MR.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Posaconazole.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Posaconazole.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Posaconazole.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Posaconazole.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Posaconazole.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Posaconazole.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Posaconazole.
TelaprevirThe serum concentration of Posaconazole can be increased when it is combined with Telaprevir.
TelavancinPosaconazole may increase the QTc-prolonging activities of Telavancin.
TelithromycinPosaconazole may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Posaconazole can be decreased when combined with Telithromycin.
TemazepamThe metabolism of Temazepam can be decreased when combined with Posaconazole.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Posaconazole.
TeniposideThe metabolism of Teniposide can be decreased when combined with Posaconazole.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Posaconazole.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Posaconazole.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Posaconazole.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Posaconazole.
TetrabenazinePosaconazole may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Posaconazole.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Posaconazole.
ThioridazinePosaconazole may increase the QTc-prolonging activities of Thioridazine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Posaconazole.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Posaconazole.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Posaconazole resulting in a loss in efficacy.
TiclopidineThe metabolism of Posaconazole can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Posaconazole.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Posaconazole.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Posaconazole.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Posaconazole.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Posaconazole.
TocilizumabThe serum concentration of Posaconazole can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Posaconazole.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Posaconazole is combined with Tolfenamic Acid.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Posaconazole.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Posaconazole.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Posaconazole.
ToremifeneThe risk or severity of adverse effects can be increased when Posaconazole is combined with Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Posaconazole.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Posaconazole.
TranilastThe risk or severity of adverse effects can be increased when Posaconazole is combined with Tranilast.
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Posaconazole.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Posaconazole.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Posaconazole.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Posaconazole.
TriazolamThe metabolism of Triazolam can be decreased when combined with Posaconazole.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Posaconazole.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Posaconazole.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Posaconazole.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Posaconazole.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Posaconazole.
UdenafilThe metabolism of Udenafil can be decreased when combined with Posaconazole.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Posaconazole.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Posaconazole.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Posaconazole.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Posaconazole.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Posaconazole.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Posaconazole.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Posaconazole.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Posaconazole.
VenlafaxineThe metabolism of Posaconazole can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Posaconazole.
VerapamilThe metabolism of Posaconazole can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Posaconazole.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Posaconazole.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Posaconazole.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Posaconazole.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Posaconazole.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Posaconazole.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Posaconazole.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Posaconazole.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Posaconazole.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Posaconazole.
VoriconazoleThe metabolism of Posaconazole can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Posaconazole.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Posaconazole.
XylometazolineThe risk or severity of adverse effects can be increased when Posaconazole is combined with Xylometazoline.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Posaconazole.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Posaconazole.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Posaconazole.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Posaconazole.
ZiconotideThe risk or severity of adverse effects can be increased when Posaconazole is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Posaconazole.
ZileutonThe metabolism of Zileuton can be decreased when combined with Posaconazole.
ZiprasidoneThe metabolism of Posaconazole can be decreased when combined with Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Posaconazole.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Posaconazole.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Posaconazole.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Posaconazole.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Posaconazole.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Yeast
Pharmacological action
yes
Actions
antagonist
General Function:
Sterol 14-demethylase activity
Specific Function:
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
Gene Name:
ERG11
Uniprot ID:
P10613
Molecular Weight:
60674.965 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM: Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother. 2004 Jun;48(6):2124-31. [PubMed:15155210 ]
  4. Li X, Brown N, Chau AS, Lopez-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM: Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004 Jan;53(1):74-80. Epub 2003 Dec 4. [PubMed:14657086 ]
  5. Bhattacharya M, Rajeshwari K, Dhingra B: Posaconazole. J Postgrad Med. 2010 Apr-Jun;56(2):163-7. doi: 10.4103/0022-3859.65281. [PubMed:20622401 ]
  6. Schiller DS, Fung HB: Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther. 2007 Sep;29(9):1862-86. [PubMed:18035188 ]
  7. Kwon DS, Mylonakis E: Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007 Jun;8(8):1167-78. [PubMed:17516880 ]
  8. Groll AH, Walsh TJ: Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther. 2005 Aug;3(4):467-87. [PubMed:16107193 ]
  9. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  10. Warrilow AG, Melo N, Martel CM, Parker JE, Nes WD, Kelly SL, Kelly DE: Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. Antimicrob Agents Chemother. 2010 Oct;54(10):4225-34. doi: 10.1128/AAC.00316-10. Epub 2010 Jul 26. [PubMed:20660663 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Nagappan V, Deresinski S: Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007 Dec 15;45(12):1610-7. doi: 10.1086/523576. [PubMed:18190324 ]
  2. Kharuzhyk SA, Matskevich SA, Filjustin AE, Bogushevich EV, Ugolkova SA: Survey of computed tomography doses and establishment of national diagnostic reference levels in the Republic of Belarus. Radiat Prot Dosimetry. 2010 Apr-May;139(1-3):367-70. doi: 10.1093/rpd/ncq070. Epub 2010 Feb 24. [PubMed:20181649 ]
  3. Kwon DS, Mylonakis E: Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007 Jun;8(8):1167-78. [PubMed:17516880 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Nagappan V, Deresinski S: Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007 Dec 15;45(12):1610-7. doi: 10.1086/523576. [PubMed:18190324 ]
Comments
comments powered by Disqus
Drug created on May 16, 2007 11:41 / Updated on September 29, 2016 02:27